On 20 October 2026, XTALPI (02228.HK) said chairman Wen Shuhao bought 3,793,000 shares, or 0.09% of issued shares, for about HKD 25 million in 7-15 October.
On 20 October 2026, Changzhou Microintelligence (03275.HK) began a global offering of 37,275,800 H shares at HKD 16.63 to 21.46, listing on 28 October 2026.
On 20 October 2026, ASMPT (00522.HK) named group chief financial officer Xu Yifan an executive director from 19 October 2026, on pay of SGD 717,000 a year.
On 20 October 2026, MANYCORE TECH (00068.HK) said four executive directors extended the lock-up on 483,200,000 shares, or 27.99% of the total, by 12 months.
On 19 Oct 2026, LYGEND RESOURCE (02245.HK) guaranteed a RMB500m credit facility for its wholly-owned Huiran Trading, flagging its gearing above 70%.
On 19 Oct 2026, GCL TECH (03800.HK) signed a non-binding MOU to buy 81.91% of Sichuan GCL Lithium for an estimated RMB 2.5bn, a connected transaction.
On 19 Oct 2026, LEADS BIOLABS-B (09887.HK) said six Weilixin and LBL-034 abstracts were published for ESMO 2026, 3 selected for preferred oral presentations.
On 19 Oct 2026, ZIJIN GOLD INTL (02259.HK) posted 9M revenue of US$5.81bn (+70%) and attributable profit of US$2.01bn (+123%), with gold output up 28%.
On 19 Oct 2026, RIBOLIFE-B (06938.HK) agreed to buy the remaining 49.71% of Sweden's Ribocure via 14,087,085 new H shares (8.26%) priced at HKD 56.83 each.
On 19 Oct 2026, SF HOLDING (06936.HK) posted Sept express revenue of RMB 20.835bn (-0.09%) and supply chain/international revenue of RMB 7.884bn (+28.13%).
On 19 Oct 2026, ZHAOJIN MINING (01818.HK) said Wang Ligang resigned as ED, remuneration committee member, VP and board secretary; Yang Tiejiang became ED.
On 19 Oct 2026, SHENZHEN INVEST (00604.HK) posted Q3 contracted sales of RMB 1.814bn and RMB 886mn of holiday subscriptions; 1 October footfall hit 180,000.
On 19 Oct 2026, MABWELL-B (02493.HK) said Phase II data for 9MW2821 in TNBC will be presented at ESMO 2026: ORR 30.0% and DCR 80.0% in 60 evaluable patients.
On 19 Oct 2026, METIS TECHBIO-P (07666.HK) signed a strategic LNP delivery deal with Eli Lilly, with an over-US$10mn upfront and up to ~US$1.1bn in milestones.
On 19 Oct 2026, BAY AREA DEV (00737.HK) signed six Shenzhen-section contracts worth ~RMB 6.66bn; TJ1/3/7 and TJ4/5 are major transactions, TJ6 discloseable.
On 19 Oct 2026, SHANDONG XINHUA (00719.HK) said nimodipine tablets passed China's generic-drug consistency evaluation, with 2025 hospital sales of ~RMB 130mn.
